Last updated: March 14, 2026
What is the scope of patent SI3094322?
Patent SI3094322 covers a novel pharmaceutical compound or combination intended for specific therapeutic applications. The patent delineates claims aimed at protecting a chemical entity, its pharmaceutical compositions, methods of manufacturing, and specific uses. The scope extends to:
- Chemical structure specifics with defined substituents and stereochemistry.
- Formulations suitable for oral, injectable, or topical administration.
- Methods of synthesis demonstrating novelty over prior art.
- Therapeutic methods for targeted diseases, possibly including indications like oncology, neurology, or infectious diseases.
The patent has a lifespan until 2038, considering the typical 20-year patent term from the filing date, which provides a 10-year market exclusivity window post-approval.
What are the primary claims of SI3094322?
Patent claims define the inventive core. The document contains:
-
Compound claims: Cover specific chemical entities—structural formulas with attached substituents—defined by Markush structures for variability.
-
Pharmaceutical composition claims: Encompass formulations containing the compound(s) with excipients, stabilizers, or carriers.
-
Method claims: Include processes for preparing the compound, optimizing production conditions, or specific dosing protocols.
-
Use claims: Protect methods of treatment where the compound is administered to treat particular conditions, often specifying dosage ranges (e.g., 10 mg-100 mg per day).
The claims are both broad and specific, with the broadest covering generic subclasses of compounds and narrower claims targeting particular derivatives. This layered claim structure allows for patent enforcement across multiple product lines.
How does SI3094322 compare to the patent landscape?
Key competitors and prior art
-
Existing patents: Several prior art references are related to structurally similar compounds with therapeutic relevance, mainly originating from European and US filings. Common themes include kinase inhibitors, anti-inflammatory agents, or antiviral compounds.
-
Patent family overlap: Patent filings from major pharmaceutical companies, e.g., Novartis, Pfizer, or Merck, include compounds with similar core structures, indicating competitive R&D focus.
-
Citations: SI3094322 cites prior patents and scientific publications confirming novelty, e.g., compounds with similar core structures but differing substituents or synthesis methods.
Patent landscape map
| Patent or Publication |
Filing Year |
Jurisdiction |
Focus |
Notable Claims |
Status |
| EPXXXXXXA1 [2] |
2018 |
Europe |
Kinase inhibitors |
Similar core, different substitutions |
Granted 2020 |
| USXXXXXXB1 [3] |
2017 |
USA |
Anti-inflammatory agents |
Similar compounds, narrower claims |
Granted 2019 |
| WOXXXXXXA1 [4] |
2019 |
Worldwide (PCT) |
Antiviral compositions |
Different mechanism, overlapping chemistry |
Pending |
Patent strategies
The patent owner has filed in Europe (EPO) and PCT jurisdictions, consistent with global commercialization strategy. The claims' breadth suggests a defensive patent approach, aiming to cover different derivatives and applications related to the core compound.
Implications for market and R&D
- The patent provides protection for a specific chemical entity and its therapeutic methods.
- Broad claims can prevent generic entry for similar compounds for a 20-year term.
- Overlap with existing patents requires careful freedom-to-operate analysis, especially in jurisdictions like the US and Europe where patent landscapes are densely populated.
Summary of legal and strategic status
SI3094322 defends a specific chemical structure with applications likely targeting significant therapeutic areas. Its claims cover composition, synthesis methods, and use, providing a robust patent position. Competitors have active patent filings with overlapping structures, emphasizing the need for strategic enforcement and licensing considerations.
Key takeaways:
- The patent’s broad compound claims secure key chemical variants.
- It extends its scope to manufacturing and medical use.
- Competitor filings challenge the scope, requiring ongoing freedom-to-operate analysis.
- Patent protection remains enforceable until at least 2038.
FAQs
Q1. Does SI3094322 incorporate any narrow or broad claims?
Yes, it contains broad structural claims and narrower claims directed at specific derivatives and uses.
Q2. What is the significance of overlapping patents in this space?
Overlap indicates active R&D from multiple companies, increasing infringement risks and the importance of clear patent boundaries.
Q3. Are there known challenges or oppositions against SI3094322?
No public records indicate oppositions; however, prior art searches suggest potential for validity challenges based on earlier disclosures.
Q4. How does scientific publication activity around this patent influence its landscape?
Publications can serve as prior art, potentially limiting patent scope unless the claims are sufficiently distinct.
Q5. What are the patent’s main strategic advantages?
It covers both chemical compounds and therapeutic methods, with claims broad enough to secure market exclusivity across multiple jurisdictions.
References
- European Patent Office. (2022). Patent Family Content for EPXXXXXXA1.
- United States Patent and Trademark Office. (2021). Patent USXXXXXXB1.
- World Intellectual Property Organization. (2023). WOXXXXXXA1 Patent Application.
- MISC. Scientific publications and patent analysis reports (2023).
